Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Enfusion reported its second quarter 2024 earnings with results aligning closely with the company's prior guidance and consistent performance expectations in the medium term.</li><li>The company posted $49.5 million in revenue, marking a 16% year-over-year growth.</li><li>The adjusted EBITDA came in at $10.1 million, translating to a 20.5% margin.</li></ul>

Enfusion reported its second quarter 2024 earnings with results aligning closely with the company's prior guidance and consistent performance expectations in the medium term.The company posted $49.5 million in revenue, marking a 16% year-over-year growth.The adjusted EBITDA came in at $10.1 million, translating to a 20.5% margin.

Is Enfusion About to Be Snapped Up? Here’s Why Acquirers Could Be Lining Up!

United States

Enfusion, Inc. provides software solutions. The Company offers software-as-a-service platform that allows clients to see and interact with all parts of the investment management lifecycle ranging from portfolio construction, trading, risk management, accounting, and operations. Enfusion serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Enfusion (ENFN US)

Is Enfusion About to Be Snapped Up? Here’s Why Acquirers Could Be Lining Up!

Enfusion reported its second quarter 2024 earnings with results aligning closely with the company's prior guidance and consistent performance...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)